Patient-reported outcomes (PRO) from a randomized, crossover trial comparing insulin degludec using FlexTouch ® with insulin glargine U100 using SoloSTAR® pen-injectors in patients with type 2 diabetes.

CONCLUSIONS: In this randomized, crossover trial, lower treatment impact and higher patient preference were reported for FlexTouch® versus SoloSTAR® pen-injectors. PMID: 30974973 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research